195 related articles for article (PubMed ID: 31786952)
1. Development and evaluation of novel miltefosine-polyphenol co-loaded second generation nano-transfersomes for the topical treatment of cutaneous leishmaniasis.
Dar MJ; McElroy CA; Khan MI; Satoskar AR; Khan GM
Expert Opin Drug Deliv; 2020 Jan; 17(1):97-110. PubMed ID: 31786952
[No Abstract] [Full Text] [Related]
2. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
3. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell.
Dar MJ; Din FU; Khan GM
Drug Deliv; 2018 Nov; 25(1):1595-1606. PubMed ID: 30105918
[TBL] [Abstract][Full Text] [Related]
4. Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous Leishmaniasis.
Dar MJ; Khalid S; Varikuti S; Satoskar AR; Khan GM
Eur J Pharm Sci; 2020 Mar; 145():105256. PubMed ID: 32032778
[TBL] [Abstract][Full Text] [Related]
5. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
Emiliano YSS; Almeida-Amaral EE
J Nat Prod; 2018 Aug; 81(8):1910-1913. PubMed ID: 30095915
[TBL] [Abstract][Full Text] [Related]
7. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
[TBL] [Abstract][Full Text] [Related]
8. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
9. Macrophage targeting with the novel carbopol-based miltefosine-loaded transfersomal gel for the treatment of cutaneous leishmaniasis:
Batool S; Zahid F; Ud-Din F; Naz SS; Dar MJ; Khan MW; Zeb A; Khan GM
Drug Dev Ind Pharm; 2021 Mar; 47(3):440-453. PubMed ID: 33615936
[TBL] [Abstract][Full Text] [Related]
10. Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis.
Khan AS; Ud Din F; Ali Z; Bibi M; Zahid F; Zeb A; Mujeeb-Ur-Rehman ; Khan GM
Int J Pharm; 2021 Jan; 593():120109. PubMed ID: 33253802
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles Loaded with a New Thiourea Derivative: Development and
Meireles PW; de Souza DPB; Rezende MG; Borsodi MPG; de Oliveira DE; da Silva LCRP; de Souza AMT; Viana GM; Rodrigues CR; do Carmo FA; de Sousa VP; Rossi-Bergmann B; Cabral LM
Curr Drug Deliv; 2020; 17(8):694-702. PubMed ID: 32621717
[TBL] [Abstract][Full Text] [Related]
12. Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis.
Khalid S; Salman S; Iqbal K; Rehman FU; Ullah I; Satoskar AR; Khan GM; Dar MJ
Nanomedicine; 2022 Feb; 40():102490. PubMed ID: 34748957
[TBL] [Abstract][Full Text] [Related]
13. Antileishmanial Agents Co-loaded in Transfersomes with Enhanced Macrophage Uptake and Reduced Toxicity.
Zahid F; Batool S; Ud-Din F; Ali Z; Nabi M; Khan S; Salman O; Khan GM
AAPS PharmSciTech; 2022 Aug; 23(6):226. PubMed ID: 35970966
[TBL] [Abstract][Full Text] [Related]
14. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
15. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
17. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
Schmidt-Ott R; Klenner T; Overath P; Aebischer T
Trans R Soc Trop Med Hyg; 1999; 93(1):85-90. PubMed ID: 10492799
[TBL] [Abstract][Full Text] [Related]
18. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
19. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of artemether-loaded niosomes in Leishmania major-induced cutaneous leishmaniasis.
Niroumand U; Motazedian MH; Ahmadi F; Asgari Q; Bahreini MS; Ghasemiyeh P; Mohammadi-Samani S
Sci Rep; 2024 May; 14(1):10073. PubMed ID: 38698123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]